Top Story

Victrelis expected to be discontinued by December

January 27, 2015

Merck expects to discontinue the manufacturing and distribution of its inhibitor Victrelis for the treatment of hepatitis C virus by December, according to a company spokesperson.

Victrelis (boceprevir) is a prescribed medication to be used in combination with peginterferon alfa and ribavirin to treat adults with chronic HCV genotype 1 infection with compensated liver disease, including cirrhosis, who have not been treated before or who have failed previous treatment.

In the Journals

Various regimens effective in treating Chinese patients with HBV

January 27, 2015
In an open-label clinical trial, treatment-naive patients with hepatitis B virus infection showed similar sustained virologic response rates to four different treatment…
In the Journals

Long-acting ART most cost-effective for patients with multiple treatment failures

January 27, 2015
Long-acting ART could be beneficial for patients with HIV, particularly those with poor adherence to daily medication, according to researchers from Massachusetts…

Clusters of underimmunized, vaccine-refusal communities identified in California

January 27, 2015
Underimmunized communities and families that refuse vaccines were found to cluster geographically, which could significantly increase the risk for an outbreak and create…
In the Journals

Skin abscesses displayed distinct cutaneous microbiota

January 27, 2015
Patients with acute skin abscesses appeared to develop abnormal microbiota in areas around the wound, according to recent findings. Researchers believe the…
More News Headlines »
CME
j526

Regimen Selection in HIV: Considering New Options to Optimize Outcomes

This activity is supported by an educational grant from Gilead Sciences Medical Affairs.

More than two decades into the antiretroviral therapy (ART) era, there are numerous options for HIV treatment. The goal…
More »
Meeting News Coverage Video
thumbnail for video 3911388507001

Student education, immunization requirements necessary to prevent outbreaks on college campuses

November 28, 2014
NEW YORK — James C. Turner, MD, executive director of the department of student health and the National Social…
More »
CME CNE CPE Video
Advances in Pharmacokinetic Enhancers in HIV Treatment: What You Need to Know to Optimize Outcomes

Advances in Pharmacokinetic Enhancers in HIV Treatment: What You Need to Know to Optimize Outcomes

This activity is supported by an educational grant from Bristol-Myers Squibb.

Protease inhibitors (PIs) have played an instrumental role in decreasing mortality andmorbidity among HIV-infected…
More »
morganatic-roan